Altre lingue Spyre Therapeutics, Inc.

Azioni

SYRE

US00773J2024

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
35,58 ^USD	+3,70%		-7,80%	+65,33%

26/03	SPYRE THERAPEUTICS, INC. : giudizio positivo da Stifel Nicolaus	ZM
01/03	SPYRE THERAPEUTICS, INC. : cambio di rotta da parte di Wells Fargo Securities	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Spyre Therapeutics Announces Grants of Inducement Awards	01/04
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	18/03
North American Morning Briefing : Powell Still in -2-	07/03
Spyre Therapeutics Announces Grants of Inducement Awards	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Spyre Therapeutics Announces Grants of Inducement Awards	01/03
Spyre Therapeutics: Q4 Earnings Snapshot	29/02
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference	26/02
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation	09/02
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors	06/02
Spyre Therapeutics, Inc. Announces Board Changes	05/02
Spyre Therapeutics Announces Grants of Inducement Awards	02/02
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	27/12
Spyre Therapeutics Announces Grants of Inducement Awards	22/12
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million	08/12
Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors	07/12
Spyre Therapeutics to Present at Upcoming Investor Conference	29/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Spyre Therapeutics, Inc.

Azioni

SYRE

US00773J2024

Altre lingue

Filtri